RxDoctor Payments Data

Lorraine Lira, MD

Neurology · Westwood, NJNPI 1649354119

Payments from drug & device makers

$11,146in general payments, 2019–2025

Across 712 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$3K
  • AbbVie$1K
  • MDD US Operations, LLC$486
  • Neurocrine Biosciences, Inc.$412
  • Lundbeck LLC$402
  • Biohaven Pharmaceuticals, Inc.$336
  • plus $5K from 50 others

What the payments were for

  • Speaking & faculty fees$300%
  • Food & beverage$11,116100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,146 in reported general payments places this provider in the 70th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$130,660
Medicare patients
281
Services billed
3,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole32$56,266
UbrelvyUbrogepant20$36,266
BriviactBrivaracetam16$20,739
FycompaPerampanel15$19,502
Aimovig AutoinjectorErenumab-Aooe13$9,823
Lacosamide33$8,473
Memantine Hcl117$6,681
Oxcarbazepine58$3,713
Carbidopa-LevodopaCarbidopa/Levodopa90$3,373
Galantamine ErGalantamine Hbr30$2,906
Gabapentin133$2,141
Carbamazepine ErCarbamazepine13$1,878
Aripiprazole17$1,726
Clonazepam138$1,602
Levetiracetam42$1,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$175$56,26632 claims
AbbVieUbrelvy$1,176$36,26620 claims
UCB, Inc.Briviact$200$20,73916 claims
Eisai Inc.Fycompa$251$19,50215 claims
Upsher-smith Laboratories LLCTopiramate$136$53833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 521 neurology providers in New Jersey.

Other neurology in Westwood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →